Category CAR-T

PIER MARIA FORNASARI
2020-01-29

European Medicines Agency Validates Kite’s Marketing Application for Chimeric Antigen Receptor (CAR) T Cell Therapy for Mantle Cell Lymphoma

Investigational KTE-X19 To Be First Chimeric Antigen Receptor (CAR) T Cell Therapy for Mantle Cell Lymphoma in Europe if Approved Kite, a Gilead Company, today announced that the company’s Marketing Authorization Application (MAA) for KTE-X19, an investigational chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL),

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2020-01-18

Exploding cancer cells can cause serious side effects in CAR-T cell therapies

Blocking a protein makes cells shrink instead, causing fewer problems Techniques to genetically modify patient immune cells have revolutionized the fight against hard-to-treat cancers. But they can come with dangerous side effects. Now, researchers have found one reason why. A particularly messy form of cell death sparks severe inflammation in patients receiving CAR-T cell immunotherapy for blood

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2019-12-05

Stanford researchers program cancer-fighting cells to resist exhaustion, attack solid tumors in mice

CAR-T cells are remarkably effective against blood cancers, but their effect can be transient as the cells become exhausted. Stanford researchers found a way to keep the cells effective in mice with human tumors. A new approach to programming cancer-fighting immune cells called CAR-T cells can prolong their activity and increase their effectiveness against human

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2019-12-04

Novartis’ new cell therapy facility could ease manufacturing squeeze for CAR-T med Kymriah

Novartis’ big push into cell and gene therapy hasn’t been the smoothest of rides, with a data manipulation scandal hamstringing Zolgensma and manufacturing concerns hurting CAR-T cancer therapy Kymriah. Could a new European facility help turn around the latter’s production bottleneck?  Novartis last week opened its newest cell and gene therapy facility in Stein, Switzerland, giving the

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2019-11-08

University of Miami Initiates CAR-T Clinical Trial in Myasthenia Gravis

Neuromuscular experts with the University of Miami Health System and the Miller School of Medicine will launch a Phase 1/2 clinical trial (NCT04146051) using the CAR-T drug, Descartes-08, to treat patients with generalized myasthenia gravis. Generalized myasthenia gravis (GMG) is a rare disease and a chronic autoimmune condition in which auto-antibodies attack specific proteins at the

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2019-10-30

AffyImmune Therapeutics Announces IND Approval for a First-in-Man Trial of Affinity-Tuned CAR-T cells for Patients with Advanced, Refractory Thyroid Cancer

AffyImmune Therapeutics, an emerging leader in CAR-T therapies, today announced FDA approval of the company’s investigational new drug (IND) application for AIC100, an affinity-tuned CAR-T cell that received Orphan designation for advanced thyroid cancer. The trial: Phase I study of AIC100 in relapsed and or refractory advanced thyroid cancer and anaplastic thyroid cancer, is sponsored by Weill

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2019-10-28

CARsgen Announces Investigational CAR-T Therapy CT053, after PRIME eligibility by EMA, Granted RMAT Designation by the U.S. FDA for R/R Multiple Myeloma

CARsgen Therapeutics Co. Ltd., a clinical-stage biopharmaceutical company today announced that the United States Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational CT053 CAR-T cell therapy. CT053 is a fully human anti-BCMA (B Cell Maturation Antigen) autologous chimeric antigen receptor (CAR) T Cell therapy for the treatment of

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2019-10-25

CAR-T cells therapy in Italy. Interview with Prof. Locatelli, Chairman of the Italian Project Group

“The Italian government has decided to invest 60 million euros on CAR-T therapies, 10 million for each of the 6 pharmaceutical workshops”. This was stated by Health Minister Roberto Speranza, explaining to the joint committees of the Senate and the House the program lines of his department. CAR-T cell therapy consists of genetic manipulation of

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2019-10-25

The Italian way to CAR-T cells.

The announcement by the Health Minister Speranza: “60 million to 6 workshops to produce Car-T against cancer” The Car-t therapies are “a strategic segment on which the government has decided to invest 60 million euros, foreseeing 10 million for each pharmaceutical workshop”, or high-tech laboratories in which the patient’s immune cells against tumors are modified.

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2019-10-08

Potency of CAR T-Cell Therapy for Myeloma May Vary by Disease Stage

Source CancerNetwork CAR T cells are a more effective therapy if manufactured for patients with multiple myeloma prior to the onset of relapsed or refractory disease, according to study results1 published in Blood Advances. “CAR T cells directed against the B-cell maturation antigen (BCMA) have demonstrated impressive initial results, but available data suggest that most patients with initial responses

Read More

No Comments InCAR-T